Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Escitalopram
2. Lexapro
1. 219861-08-2
2. Lexapro
3. (s)-citalopram Oxalate
4. Cipralex
5. Escitalopram (oxalate)
6. (s)-(+)citalopram Oxalate
7. Lu 26-054-0
8. Escitalopram (as Oxalate)
9. Citalopram Oxalate, (s)-
10. Nsc-758934
11. 5u85dbw7lo
12. Lu-26-054-0
13. (s)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate
14. (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic Acid
15. Lu-26-054-o
16. Ncgc00095903-01
17. Dsstox_cid_26003
18. Dsstox_rid_81282
19. S-(+)-1-(3-(dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile Oxalate
20. Dsstox_gsid_46003
21. S-(+)-5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, Oxalate
22. Cas-219861-08-2
23. Escitalopram Oxalate [usan]
24. Gaudium
25. Entact
26. (s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate
27. Lexapro (tn)
28. Escitalopram Oxalate Inn
29. Unii-5u85dbw7lo
30. Schembl35123
31. Mls001401408
32. Spectrum1505216
33. (+)-(s)-citalopram Oxalate
34. Mld-55
35. (s)-citalopram Oxalate- Bio-x
36. Chembl1200322
37. Dtxsid1046003
38. Escitalopram Oxalate (jan/usp)
39. Escitalopram Oxalate [mi]
40. C20h21fn2o.c2h2o4
41. Escitalopram Oxalate [usan:usp]
42. Escitalopram Oxalate [jan]
43. Hms2051d11
44. Hms2231m16
45. Hms3370i17
46. Hms3393d11
47. Hms3713d16
48. Pharmakon1600-01505216
49. Bcp05686
50. Escitalopram Oxalate [vandf]
51. Tox21_111535
52. Ccg-39559
53. Escitalopram Oxalate [mart.]
54. Hy-14258a
55. Mfcd06407826
56. Nsc758934
57. Escitalopram Oxalate [usp-rs]
58. Escitalopram Oxalate [who-dd]
59. Akos016340275
60. Tox21_111535_1
61. Ac-6770
62. Cs-2054
63. Ks-1263
64. Nc00194
65. Nsc 758934
66. Sb17454
67. Ncgc00178555-02
68. 5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1s)-, Ethanedioate (1:1)
69. Bc164423
70. Escitalopram Oxalate [orange Book]
71. Smr000469191
72. Escitalopram Oxalate [ep Monograph]
73. Escitalopram Oxalate [usp Monograph]
74. E0958
75. D02567
76. Escitalopram Oxalate, >=98% (hplc), Powder
77. 861e082
78. A852070
79. Sr-01000763053
80. Sr-01000763053-3
81. Q27262882
82. Escitalopram Oxalate, Europepharmacopoeia (ep) Reference Standard
83. Escitalopram Oxalate, United States Pharmacopeia (usp) Reference Standard
84. Escitalopram For System Suitability, Europepharmacopoeia (ep) Reference Standard
85. Escitalopram Oxalate, Pharmaceutical Secondary Standard; Certified Reference Material
86. (+)-(s)-1-[3-(dimethylamino)propyl] -1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancar Bonitrile Oxalate
87. (+)-(s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Oxalate
88. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile Oxalate
89. 5-isobenzofurancarbonitrile,1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1s)-,ethanedioate (1:1)
Molecular Weight | 414.4 g/mol |
---|---|
Molecular Formula | C22H23FN2O5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 414.15910000 g/mol |
Monoisotopic Mass | 414.15910000 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 537 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Escitalopram oxalate |
PubMed Health | Escitalopram (By mouth) |
Drug Classes | Antianxiety, Antidepressant |
Drug Label | Escitalopramoxalate USPis an orally administered selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+... |
Active Ingredient | Escitalopram oxalate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | 5mg; eq 5mg base; eq 5mg base/5ml; 10mg; eq 20mg base; eq 10mg base; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Watson Labs; Amneal Pharms; Mylan Pharma; Teva Pharms; Macleods Pharms; Caraco; Jubilant Generics; Sti Pharma; Apotex; Accord Hlthcare; Hetero Labs Ltd Iii; Aurobindo Pharma; Teva Pharms Usa; Taro; Torrent Pharms; Lupin; Zydus Pharms Usa; Dr Reddys Labs; |
2 of 4 | |
---|---|
Drug Name | Lexapro |
Drug Label | Lexapro (escitalopram oxalate) is an orally administered selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designate... |
Active Ingredient | Escitalopram oxalate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | eq 5mg base; eq 5mg base/5ml; eq 20mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
3 of 4 | |
---|---|
Drug Name | Escitalopram oxalate |
PubMed Health | Escitalopram (By mouth) |
Drug Classes | Antianxiety, Antidepressant |
Drug Label | Escitalopramoxalate USPis an orally administered selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+... |
Active Ingredient | Escitalopram oxalate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | 5mg; eq 5mg base; eq 5mg base/5ml; 10mg; eq 20mg base; eq 10mg base; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Watson Labs; Amneal Pharms; Mylan Pharma; Teva Pharms; Macleods Pharms; Caraco; Jubilant Generics; Sti Pharma; Apotex; Accord Hlthcare; Hetero Labs Ltd Iii; Aurobindo Pharma; Teva Pharms Usa; Taro; Torrent Pharms; Lupin; Zydus Pharms Usa; Dr Reddys Labs; |
4 of 4 | |
---|---|
Drug Name | Lexapro |
Drug Label | Lexapro (escitalopram oxalate) is an orally administered selective serotonin reuptake inhibitor (SSRI). Escitalopram is the pure S-enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designate... |
Active Ingredient | Escitalopram oxalate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | eq 5mg base; eq 5mg base/5ml; eq 20mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
Selective Serotonin Reuptake Inhibitors
Compounds that specifically inhibit the reuptake of serotonin in the brain. (See all compounds classified as Selective Serotonin Reuptake Inhibitors.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
84
PharmaCompass offers a list of Escitalopram Oxalate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Escitalopram Oxalate manufacturer or Escitalopram Oxalate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Escitalopram Oxalate manufacturer or Escitalopram Oxalate supplier.
PharmaCompass also assists you with knowing the Escitalopram Oxalate API Price utilized in the formulation of products. Escitalopram Oxalate API Price is not always fixed or binding as the Escitalopram Oxalate Price is obtained through a variety of data sources. The Escitalopram Oxalate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ECT-12003 (S-CITALOPRAM OXALATE) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ECT-12003 (S-CITALOPRAM OXALATE), including repackagers and relabelers. The FDA regulates ECT-12003 (S-CITALOPRAM OXALATE) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ECT-12003 (S-CITALOPRAM OXALATE) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) supplier is an individual or a company that provides ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) or ECT-12003 (S-CITALOPRAM OXALATE) finished formulations upon request. The ECT-12003 (S-CITALOPRAM OXALATE) suppliers may include ECT-12003 (S-CITALOPRAM OXALATE) API manufacturers, exporters, distributors and traders.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) DMF (Drug Master File) is a document detailing the whole manufacturing process of ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) in detail. Different forms of ECT-12003 (S-CITALOPRAM OXALATE) DMFs exist exist since differing nations have different regulations, such as ECT-12003 (S-CITALOPRAM OXALATE) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ECT-12003 (S-CITALOPRAM OXALATE) DMF submitted to regulatory agencies in the US is known as a USDMF. ECT-12003 (S-CITALOPRAM OXALATE) USDMF includes data on ECT-12003 (S-CITALOPRAM OXALATE)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ECT-12003 (S-CITALOPRAM OXALATE) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ECT-12003 (S-CITALOPRAM OXALATE) Drug Master File in Japan (ECT-12003 (S-CITALOPRAM OXALATE) JDMF) empowers ECT-12003 (S-CITALOPRAM OXALATE) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ECT-12003 (S-CITALOPRAM OXALATE) JDMF during the approval evaluation for pharmaceutical products. At the time of ECT-12003 (S-CITALOPRAM OXALATE) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ECT-12003 (S-CITALOPRAM OXALATE) Drug Master File in Korea (ECT-12003 (S-CITALOPRAM OXALATE) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ECT-12003 (S-CITALOPRAM OXALATE). The MFDS reviews the ECT-12003 (S-CITALOPRAM OXALATE) KDMF as part of the drug registration process and uses the information provided in the ECT-12003 (S-CITALOPRAM OXALATE) KDMF to evaluate the safety and efficacy of the drug.
After submitting a ECT-12003 (S-CITALOPRAM OXALATE) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ECT-12003 (S-CITALOPRAM OXALATE) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with KDMF on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) CEP of the European Pharmacopoeia monograph is often referred to as a ECT-12003 (S-CITALOPRAM OXALATE) Certificate of Suitability (COS). The purpose of a ECT-12003 (S-CITALOPRAM OXALATE) CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ECT-12003 (S-CITALOPRAM OXALATE) EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ECT-12003 (S-CITALOPRAM OXALATE) to their clients by showing that a ECT-12003 (S-CITALOPRAM OXALATE) CEP has been issued for it. The manufacturer submits a ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) as part of the market authorization procedure, and it takes on the role of a ECT-12003 (S-CITALOPRAM OXALATE) CEP holder for the record. Additionally, the data presented in the ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ECT-12003 (S-CITALOPRAM OXALATE) DMF.
A ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ECT-12003 (S-CITALOPRAM OXALATE) CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with CEP (COS) on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) written confirmation (ECT-12003 (S-CITALOPRAM OXALATE) WC) is an official document issued by a regulatory agency to a ECT-12003 (S-CITALOPRAM OXALATE) manufacturer, verifying that the manufacturing facility of a ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ECT-12003 (S-CITALOPRAM OXALATE) APIs or ECT-12003 (S-CITALOPRAM OXALATE) finished pharmaceutical products to another nation, regulatory agencies frequently require a ECT-12003 (S-CITALOPRAM OXALATE) WC (written confirmation) as part of the regulatory process.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ECT-12003 (S-CITALOPRAM OXALATE) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ECT-12003 (S-CITALOPRAM OXALATE) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ECT-12003 (S-CITALOPRAM OXALATE) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ECT-12003 (S-CITALOPRAM OXALATE) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ECT-12003 (S-CITALOPRAM OXALATE) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with NDC on PharmaCompass.
ECT-12003 (S-CITALOPRAM OXALATE) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ECT-12003 (S-CITALOPRAM OXALATE) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ECT-12003 (S-CITALOPRAM OXALATE) GMP manufacturer or ECT-12003 (S-CITALOPRAM OXALATE) GMP API supplier for your needs.
A ECT-12003 (S-CITALOPRAM OXALATE) CoA (Certificate of Analysis) is a formal document that attests to ECT-12003 (S-CITALOPRAM OXALATE)'s compliance with ECT-12003 (S-CITALOPRAM OXALATE) specifications and serves as a tool for batch-level quality control.
ECT-12003 (S-CITALOPRAM OXALATE) CoA mostly includes findings from lab analyses of a specific batch. For each ECT-12003 (S-CITALOPRAM OXALATE) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ECT-12003 (S-CITALOPRAM OXALATE) may be tested according to a variety of international standards, such as European Pharmacopoeia (ECT-12003 (S-CITALOPRAM OXALATE) EP), ECT-12003 (S-CITALOPRAM OXALATE) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ECT-12003 (S-CITALOPRAM OXALATE) USP).